CD274 and neoplasm: Improving our understanding of PD-L1 assay variation and interchangeability is critical as the current licensing of nivolumab with first-line platinum–fluoropyrimidine chemotherapies in Europe, for example, is restricted to patients with PD-L1 CPS ≥ 5 tumours and assay-independent.